♦ The funding of rituximab (Rituxan) for the treatment of rheumatoid arthritis was initially reviewed in February 2007. At that time, the Committee
Guidelines for the use and administration of Rituximab in Rheumatoid Arthritis Version 14 Minor update edits 22.7.09 Susan Oliver 1 of 13 ADMINISTRATION
out, with only 5 patients having a baseline visit and no subsequent measures. Table 1 summarizes the baseline demographic features of the 2 treatment groups.
Table 2. Deﬁnitions of key terms and key assumptions for clinical scenarios for the 2012 ACR recommendations update for the treatment of RA* Deﬁnitions
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a ...
Rheumatoid Arthritis (RA) B cell T cell Antigen-presenting cells B cell or macrophage Synoviocytes Pannus Articular cartilage Chondrocytes Macrophage HLA -DR
Guidelines doi:10.1093/rheumatology/ker106b BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis Marwan Bukhari1, Rikki Abernethy2, Chris Deighton3 ...
S14 Supplement to Journal of Managed Care Pharmacy JMCP November/December 2011 Vol. 17, No. 9-b www.amcp.org Biologic Agents in Rheumatoid Arthritis:
lymphoma, non-gastric MALT lymphoma, post-transplant lymphoproliferative disorders, primary cutaneous B-cell lymphoma, and splenic marginal zone lymphoma)
6 Treatment of rheumatoid arthritis and other inflammatory disorders with biological drugs Objectives: * Be able to give examples of inflammatory disease, notably